Altimmune (NASDAQ:ALT) Receives Buy Rating from HC Wainwright

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $12.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 26.05% from the company’s current price.

A number of other equities analysts also recently commented on ALT. UBS Group started coverage on Altimmune in a report on Tuesday. They set a “buy” rating and a $26.00 target price for the company. B. Riley reaffirmed a “buy” rating and issued a $20.00 target price on shares of Altimmune in a research report on Monday, August 12th. Finally, Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Altimmune Stock Performance

NASDAQ:ALT opened at $9.52 on Thursday. Altimmune has a fifty-two week low of $2.34 and a fifty-two week high of $14.84. The business has a 50 day moving average price of $6.95 and a 200-day moving average price of $6.89. The firm has a market cap of $676.59 million, a PE ratio of -6.14 and a beta of 0.09.

Altimmune (NASDAQ:ALT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. The company had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 52.60% and a negative net margin of 199,076.92%. During the same period in the previous year, the business earned ($0.39) earnings per share. Research analysts predict that Altimmune will post -0.54 EPS for the current year.

Insider Buying and Selling at Altimmune

In other Altimmune news, Director David Drutz sold 16,011 shares of Altimmune stock in a transaction on Monday, August 19th. The stock was sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the transaction, the director now owns 41,958 shares in the company, valued at approximately $289,510.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ALT. Farallon Capital Management LLC lifted its position in Altimmune by 1,282.4% in the 1st quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock valued at $4,785,000 after acquiring an additional 436,000 shares in the last quarter. Knoll Capital Management LLC boosted its position in shares of Altimmune by 183.6% during the first quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock valued at $5,774,000 after buying an additional 367,219 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after buying an additional 335,444 shares in the last quarter. SG Americas Securities LLC raised its position in Altimmune by 542.8% in the 2nd quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock worth $1,693,000 after buying an additional 214,968 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. bought a new position in Altimmune during the 2nd quarter valued at about $860,000. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.